Australia - English - Department of Health (Therapeutic Goods Administration)

allmedic pty ltd - diethylamino hydroxybenzoyl hexyl benzoate, quantity: 50 mg/g; ethylhexyl triazone, quantity: 20 mg/g; octyl methoxycinnamate, quantity: 50 mg/g; bemotrizinol, quantity: 50 mg/g; phenylbenzimidazole sulfonic acid, quantity: 10 mg/g; methylene bis-benzotriazolyl tetramethylbutylphenol, quantity: 60 mg/g - cream - excipient ingredients: ethylhexylglycerin; purified water; sodium stearoyl glutamate; piroctone olamine; butylated hydroxytoluene; triacontanyl pvp; sodium hydroxide; nicotinamide; propylene glycol dibenzoate; phenoxyethanol; lactic acid; phenyl trimethicone; cetostearyl alcohol; medium chain triglycerides; neopentyl glycol diheptanoate; potassium cetyl phosphate; propylene glycol; xanthan gum; decyl glucoside; fragrance (perfume) - may reduce the risk of some skin cancers (sunscreen) ; spf 50 broad spectrum high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 10 mg - lipid modifying agents

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 20 mg - lipid modifying agents

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 40 mg - lipid modifying agents

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 80 mg - lipid modifying agents

Malta - English - Medicines Authority

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - rivaroxaban - film-coated tablet - rivaroxaban 15 mg - antithrombotic agents

Malta - English - Medicines Authority

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - rivaroxaban - film-coated tablet - rivaroxaban 20 mg - antithrombotic agents

European Union - English - EMA (European Medicines Agency)

roche registration ltd. - daclizumab - graft rejection; kidney transplantation - immunosuppressants - zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including cyclosporine and corticosteroids in patients who are not highly immunised.

Ireland - English - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - human plasma protein >95% immunoglobulins - solution for injection - 160 gram(s)/litre - immunoglobulins, normal human; immunoglobulins, normal human, for extravascular adm. - immune sera and immunoglobulins: immunoglobulins, normal human, for extravascular administration - replacement therapy in adults and children in primary immunodeficiency syndromes such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia - common variable immunodeficiency - severe combined immunodeficiency - igg subclass deficiencies with recurrent infections

European Union - English - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - busulfan - hematopoietic stem cell transplantation - alkyl sulfonates - busulfan fresenius kabi followed by cyclophosphamide (bucy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (hpct) in adult patients when the combination is considered the best available option.busulfan fresenius kabi followed by cyclophosphamide (bucy4) or melphalan (bumel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.